NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
Nyenta.com/10303210

WILMINGTON, Del., Feb. 6, 2025 ~ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and its subsidiary, HOPE Therapeutics, Inc., have announced that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting an update on the company at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The conference will take place virtually on February 11th-12th.

The presentation is scheduled for Wednesday, February 12th from 9:20 – 9:50 AM EST. Interested parties can access a live webcast of the presentation on NRX Events within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.

In addition to the presentation, management will also be available for one-on-one meetings in New York from February 10th-12th. Those interested in scheduling a meeting can contact NRx Pharmaceuticals.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders such as suicidal bipolar depression, chronic pain, and PTSD. The company's lead product candidate is NRX-101, which has been designated as an FDA Breakthrough Therapy for treatment-resistant bipolar depression and chronic pain. The company plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. Additionally, NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI.

More on Nyenta.com

• The Joy of Gifting Wine and Spirits!
• EnergyStrat Launches Global LNG Risk Outlook 2025–2030
• Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
• Loa Carbon Announces Appointment of Adam Goldstein to Board of Directors
• Holiday Decorations Most Likely to Cause Injuries

Recently, NRx has initiated a New Drug Application filing for another product candidate, NRX-100 (IV ketamine), which has shown promising results in treating suicidal depression. This filing is based on well-controlled clinical trials conducted under the US National Institutes of Health and newly obtained data from French health authorities under a data sharing agreement. The US FDA has granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality.

HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, is a development stage healthcare delivery company. Its goal is to establish a network of interventional psychiatry clinics that offer ketamine transcranial magnetics stimulation (TMS) and other life-saving therapies to patients with suicidal depression and related disorders. The company also plans to develop a digital therapeutic-enabled platform to enhance and maintain the clinical benefits of NMDA-targeted drug therapy.

This announcement serves as notice regarding NRx Pharmaceuticals' participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference and its ongoing efforts in developing innovative treatments for central nervous system disorders. Interested parties are encouraged to attend the presentation or schedule a meeting with management for further information.

---

Show All News | Report Violation